China The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial efficacy evaluation. 19 of 24 patients with relapsed and refractory multiple myeloma showed complete response Zonghai Li, CARSgen Therapeutics…
Hong Kong Professor James Chim, chairman and founder of the Hong Kong Society of Myeloma, shares the history and key objectives of the organization. He also elaborates on the recent milestones achieved regarding the treatment of the rare disease. Can you begin by introducing the Hong Kong Society of Myeloma and what…
Pharma Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics of the Italian market that make it especially promising to Celgene. Mr. Frega, to start off, Imnovid, Celgene’s newest oral treatment…
Pharma Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help to tackle the current difficulties in accessing the Dutch market, while implementing new innovative pricing models such as pay for benefit.…
See our Cookie Privacy Policy Here
